WebApr 19, 2024 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the potential treatment of patients with anaemia of chronic kidney disease (CKD). WebJul 19, 2024 · GlaxoSmithKline (GSK) has reported positive headline data gathered from five clinical trials of the Phase III ASCEND programme of daprodustat to treat anaemia in chronic kidney disease (CKD) patients. Daprodustat is an experimental, oral inhibitor of hypoxia-inducible factor prolyl hydroxylase.
Home GSK US
WebJan 24, 2024 · Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) ... GlaxoSmithKline: ClinicalTrials.gov Identifier: NCT03029208 Other Study ID Numbers: 201410 2016-000507-86 ( EudraCT Number ) WebJun 29, 2024 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anaemia due to chronic kidney disease … pk olie
GSK announces positive Phase III efficacy and safety data for ...
WebNov 25, 2016 · GlaxoSmithKline has begun late stage development of its daprodustat, for anaemia associated with chronic kidney disease. GSK said the phase 3 programme included two studies evaluating the... WebFeb 1, 2024 · About anemia of chronic kidney disease CKD, characterised by progressive loss of kidney function, is an increasing global public health burden. [iii] Risk factors for CKD include hypertension, diabetes, obesity and primary renal disorders. iii Furthermore, CKD is an independent risk factor for cardiovascular disease. iii Anemia is an important ... WebSep 6, 2024 · CKD, characterised by progressive loss of kidney function, is an increasing global public health burden. [3] Risk factors for CKD include hypertension, diabetes, obesity and primary renal disorders. [3] Furthermore, CKD is an independent risk factor for cardiovascular disease. [3] Anaemia is an important and frequent complication of CKD. [4] pk neuhaus